- Q1 2014 financial results were nothing to get excited about. We believe it may take 1-2 more quarters before real progress is demonstrated.
- Despite being early on our call, we are confident that Cytomedix has a bright future based on sizable revenues opportunities for both Angel and AutoloGel.
- Cytomedix' valuation is extremely attractive. We believe the shares are worth 3x the current value. We expect significant progress to be demonstrated by year end 2014.